Association of biomarkers of inflammation and cell adhesion with lung function in the elderly: a population-based study

BMC Geriatrics

Christer Janson¹  Johan Sundström²  Lars Lind²  Inga Sif Ólafsdóttir¹  Antje Kuhlmann¹ 

[1] Department of Medical Sciences, Respiratory Medicine & Allergology, Uppsala University, Uppsala University Hospital, 751 85, Uppsala, Sweden;Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala University Hospital, 751 85, Uppsala, Sweden

关键词: Gender;    Biomarkers;    COPD;    FVC;    FEV₁;    Lung function;   

Others  :  857494
DOI  :  10.1186/1471-2318-13-82

 received in 2013-04-10, accepted in 2013-07-30,  发布年份 2013

【 摘 要 】

Background

Low lung function is associated with increased morbidity and mortality. It is therefore of interest to identify biomarkers that are associated with impaired lung function. The aim of the study was to analyse associations of biomarkers and combinations of biomarkers with lung function in an elderly general population.

Methods

Lung function (FEV₁ and FVC) and a panel of 15 inflammatory markers from blood samples were analysed in 888 subjects aged 70 years. Biomarkers included cytokines, chemokines, adhesion molecules, C-reactive protein (CRP) and leukocyte count.

Results

Leukocyte count and CRP were independently associated with FEV₁ after adjustments for other inflammatory markers, sex, BMI, current smoking and pack-years of smoking. In a similar model, leukocyte count and vascular cell adhesion protein 1 (VCAM-1) were the biomarkers that were significantly associated with FVC. Subjects that had both leukocyte count and CRP in the lowest tertile had a FEV₁ that was 9% of predicted higher than subjects with leukocyte count and CRP in the highest tertile (103±16 vs. 94±21% of predicted, p=0.0002) (mean±SD). A difference of 8% of predicted in FVC was found between subjects with leukocyte count and VCAM-1 in the lowest and highest tertiles, respectively (106±18 vs. 98±19% of predicted, p=0.002).

Conclusion

Leucocyte count, CRP and VCAM-1 were found to relate to poorer lung function. A dose related association was found for the combination leukocyte count and CRP towards FEV₁ and leukocyte and VCAM-1 towards FVC. This indicates that combination of two biomarkers yielded more information than assessing them one by one when analysing the association between systemic inflammation and lung function.

【 授权许可】

   
2013 Kuhlmann et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Beaty TH, Cohen BH, Newill CA, Menkes HA, Diamond EL, Chen CJ: Impaired pulmonary function as a risk factor for mortality. Am J Epidemiol 1982, 116:102-113.
• [2]Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M: Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J 1991, 4:1080-1087.
• [3]Engström G, Janzon L: Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet Med 2002, 19:167-170.
• [4]Engström G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, Lindgärde F: Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002, 106:2555-2560.
• [5]Margretardottir OB, Thorleifsson SJ, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, Buist AS, Gíslason T: Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study. COPD 2009, 6:250-255.
• [6]Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E, ECHOS Lung Function Study Group: The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010, 12:685-691.
• [7]Burney PGJ, Hooper R: Forced vital capacity, airway obstruction and survival in a general population sample from the USA. Thorax 2011, 66:49-54.
• [8]Gimeno D, Delclos GL, Ferrie JE, De Vogli R, Elovainio M, Marmot MG, Kivimäki M: Association of CRP and IL-6 with lung function in a middle-aged population initially free from self-reported respiratory problems: the Whitehall II study. Eur J Epidemiol 2011, 26:135-144.
• [9]Mannino DM, Valvi D, Mullerova H, Tal-Singer R: Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD 2012, 9:359-366.
• [10]Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R: Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators: COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12:146. BioMed Central Full Text
• [11]Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Lipinska I, O’Connor GT, Benjamin EJ: Systemic inflammation and COPD: the Framingham heart study. Chest 2008, 133:19-25.
• [12]Gan WQ, Man SFP, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
• [13]Chang SS, Vaz Fragoso CA, Van Ness PH, Fried LP, Tinetti ME: Association between combined interleukin-6 and C-reactive protein levels and pulmonary function in older women: results from the Women’s Health and Aging Studies I and II. J Am Geriatr Soc 2011, 59:113-119.
• [14]Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, Macnee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A, ECLIPSE Investigators: Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072.
• [15]Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG: Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:982-988.
• [16]Thorleifsson SJ, Margretardottir OB, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, Buist AS, Gíslason T: Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med 2009, 103:1548-1553.
• [17]Olafsdóttir IS, Gíslason T, Thjódleifsson B, Olafsson I, Gíslason D, Jõgi R, Janson C: Gender differences in the association between C-reactive protein, lung function impairment, and COPD. Int J Chron Obstruct Pulmon Dis 2007, 2:635-642.
• [18]Olafsdóttir IS, Janson C, Lind L, Hulthe J, Gunnbjörnsdóttir M, Sundström J: Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study. Respirology 2010, 15:530-535.
• [19]Olafsdóttir IS, Gíslason T, Gudnason V, Benediktsdottir B, Olafsson I, Aspelund T, Thjódleifsson B, Janson C: CRP is associated with lung function decline in men but not women: a prospective study. Respir Med 2013, 107:91-97.
• [20]Lind L, Fors N, Hall J, Marttala K, Stenborg A: A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005, 25:2368-2375.
• [21]Engström G, Gerhardsson de Verdier M, Dahlbäck M, Janson C, Lind L: BP variability and cardiovascular autonomic function in relation to forced expiratory volume: a population-based study. Chest 2009, 136:177-183.
• [22]Anon: Standardization of spirometry, 1994 update: American Thoracic society. Am J Respir Crit Care Med 1995, 152:1107-1136.
• [23]Anon: Standardisation of lung function tests: European community for coal steel. Clin Respir Phys 1983, 19(Suppl 5):22-27.
• [24]Lind L, Siegbahn A, Hulthe J, Elmgren A: C-reactive protein and e-selectin levels are related to vasodilation in resistance, but not conductance arteries in the elderly: the prospective investigation of the vasculature in uppsala seniors (PIVUS) study. Atherosclerosis 2008, 199:129-137.
• [25]Fitzgerald SP, McConnell RI, Huxley A: Simultaneous analysis of circulating human cytokines using a high-sensitivity cytokine biochip array. J Proteome Res 2008, 7:450-455.
• [26]Cazzola M, Novelli G: Biomarkers in COPD. Pulm Pharmacol Ther 2010, 23:493-500.
• [27]Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J, EPI-SCAN Steering Committee: Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11:63. BioMed Central Full Text
• [28]Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, MacCallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128:1995-2004.
• [29]Chan-Yeung M, Abboud R, Buncio AD, Vedal S: Peripheral leucocyte count and longitudinal decline in lung function. Thorax 1988, 43:462-466.
• [30]Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y: Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009, 103:1231-1238.
• [31]Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janciauskiene S: Analysis of systemic biomarkers in COPD patients. COPD 2004, 1:155-164.
• [32]Janson C, Ludviksdottir D, Gunnbjörnsdóttir M, Björnsson EH, Håkansson L, Venge P, BHR-study group: Circulating adhesion molecules in allergic and non-allergic asthma. Respir Med 2005, 99:45-51.
• [33]Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM: Systemic effects of smoking. Chest 2007, 131:1557-1566.
• [34]Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
• [35]Di Napoli M, Godoy DA, Campi V, Masotti L, Smith CJ, Parry Jones AR, Hopkins SJ, Slevin M, Papa F, Mogoanta L, Pirici D, Wagner AP: C-reactive protein in intracerebral hemorrhage. Neurology 2012, 79:690-699.
• [36]Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-97.
• [37]Cote CG, Chapman KR: Diagnosis and treatment considerations for women with COPD. Int J Clin Pract 2009, 63:486-493.
• [38]Martinez FJ, Curtis JL, Sciurba F, Mumford J, Giardino ND, Weinmann G, Kazerooni E, Murray S, Criner GJ, Sin DD, Hogg J, Ries AL, Han M, Fishman AP, Make B, Hoffman EA, Mohsenifar Z, Wise R: National emphysema treatment trial research group: sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 2007, 176:243-252.